Literature DB >> 10197073

The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects.

T Zimmermann-Belsing1, M Dreyer, J J Holst, U Feldt-Rasmussen.   

Abstract

OBJECTIVE: Previous studies of leptin in thyrotoxic human subjects have been short-term and cross-sectional. We have measured serum leptin concentrations in thyrotoxic patients in order to study the influence of endogenous thyroid hormones on the relationship between serum leptin and fat mass. DESIGN PATIENTS, MEASUREMENTS: In 10 fasting thyrotoxic patients (8 females, 2 males, mean age: 51 years) we measured serum leptin (microgram/l), total thyroxine (TT4), total triiodothyronine (TT3), thyrotropin (TSH) and by Dual Energy X-ray Absorptiometry (DEXA) total fat mass (TFM, kg) at time of diagnosis (0 months, baseline) and during 12 months treatment with thiamazole. For comparison 16 fasting thiamazole-treated euthyroid patients (14 females, 2 males, mean age: 38 years) were studied after one year follow-up (26 months (15-48)) and 18 normal controls (12 females, 6 males, mean age: 39 years).
RESULTS: The serum leptin concentration was 9.1 (1.3 micrograms/l (mean (SEM) in the thyrotoxic patients and increased significantly to 16.0 (1.3 micrograms/l (P < 0.0005) after 12 months treatment compared to both normal subjects and their own baseline. There was a significant correlation between serum leptin concentration and TFM in the normal control group (r = 0.79, P < 0.00009), in the thiamazole-treated euthyroid group (r = 0.85, P < 0.00003) and in the baseline thyrotoxic group (r = 0.84, P < 0.002) but the serum leptin/TFM ratio increased significantly during 12 months of antithyroid drug treatment from 0.34 (1.2 micrograms/l/kg to 0.53 (1.2 micrograms/l/kg (P < 0.03).
CONCLUSION: The thiamazole-treated thyrotoxic patients increased their serum leptin concentrations during 12 months antithyroid drug treatment without a significant corresponding degree of changes in TFM as expected from normal controls. It is suggested that the metabolic state in thyrotoxic patients can influence the regulation of serum leptin concentrations without any associated changes in TFM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10197073     DOI: 10.1046/j.1365-2265.1998.00627.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

Review 1.  Thyroid function and obesity.

Authors:  Peter Laurberg; Nils Knudsen; Stig Andersen; Allan Carlé; Inge Bülow Pedersen; Jesper Karmisholt
Journal:  Eur Thyroid J       Date:  2012-09-22

2.  Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?

Authors:  Tina Z Belsing; Charlotte Tofteng; Bente L Langdahl; Peder Charles; Ulla Feldt-Rasmussen
Journal:  Nutr Metab (Lond)       Date:  2010-09-01       Impact factor: 4.169

3.  Evaluation of serum leptin levels and thyroid function in morbidly obese patients treated with bariatric surgery.

Authors:  S Alagna; M L Cossu; A Masala; M M Atzeni; M Ruggiu; F M Satta; E Fais; P P Rovasio; G Noya
Journal:  Eat Weight Disord       Date:  2003-06       Impact factor: 4.652

4.  Leptin, thyrotropin, and thyroid hormones in obese/overweight women before and after two levels of energy deficit.

Authors:  Lucyna Kozłowska; Danuta Rosołowska-Huszcz
Journal:  Endocrine       Date:  2004-07       Impact factor: 3.633

5.  Weight gain during the treatment of thyrotoxicosis using conventional thyrostatic treatment.

Authors:  M S Rathi; J N Miles; P E Jennings
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

6.  Weight Gain and Body Composition Changes during the Transition of Thyroid Function in Patients with Graves' Disease Undergoing Radioiodine Treatment.

Authors:  Zhenqin Cai; Qiyu Chen; Yan Ling
Journal:  Int J Endocrinol       Date:  2022-07-18       Impact factor: 2.803

Review 7.  Levothyroxine Therapy in Elderly Patients With Hypothyroidism.

Authors:  Grigoris Effraimidis; Torquil Watt; Ulla Feldt-Rasmussen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-12       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.